132 related articles for article (PubMed ID: 37171460)
1. Behavioral effects induced by the cannabidiol analogs HU-502 and HU-556.
Colodete DAE; Silva NR; Pedrazzi JFC; Fogaça MV; Cortez I; Del-Bel EA; Breuer A; Mechoulam R; Gomes FV; Guimarães FS
Behav Pharmacol; 2023 Jun; 34(4):213-224. PubMed ID: 37171460
[TBL] [Abstract][Full Text] [Related]
2. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
El-Alfy AT; Ivey K; Robinson K; Ahmed S; Radwan M; Slade D; Khan I; ElSohly M; Ross S
Pharmacol Biochem Behav; 2010 Jun; 95(4):434-42. PubMed ID: 20332000
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
5. Effects of cannabidiol and Δ9-tetrahydrocannabinol in the elevated plus maze in mice.
Liu J; Scott BW; Burnham WM
Behav Pharmacol; 2022 Apr; 33(2&3):206-212. PubMed ID: 33883447
[TBL] [Abstract][Full Text] [Related]
6. Female but not male rats show biphasic effects of low doses of Δ
Salviato BZ; Raymundi AM; Rodrigues da Silva T; Salemme BW; Batista Sohn JM; Araújo FS; Guimarães FS; Bertoglio LJ; Stern CA
Neuropharmacology; 2021 Sep; 196():108684. PubMed ID: 34181978
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze.
Guimarães FS; de Aguiar JC; Mechoulam R; Breuer A
Gen Pharmacol; 1994 Jan; 25(1):161-4. PubMed ID: 7913072
[TBL] [Abstract][Full Text] [Related]
8. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
[TBL] [Abstract][Full Text] [Related]
9. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.
Moreira FA; Guimarães FS
Eur J Pharmacol; 2005 Apr; 512(2-3):199-205. PubMed ID: 15840405
[TBL] [Abstract][Full Text] [Related]
10. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.
Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R
Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755
[TBL] [Abstract][Full Text] [Related]
11. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101.
Stollenwerk TM; Pollock S; Hillard CJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500787
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.
Sartim AG; Marques J; Silveira KM; Gobira PH; Guimarães FS; Wegener G; Joca SR
Neuropharmacology; 2021 Sep; 195():108679. PubMed ID: 34157363
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.
Pedrazzi JF; Issy AC; Gomes FV; Guimarães FS; Del-Bel EA
Psychopharmacology (Berl); 2015 Aug; 232(16):3057-65. PubMed ID: 25943166
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.
Pedrazzi JFC; Sales AJ; Guimarães FS; Joca SRL; Crippa JAS; Del Bel E
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Dec; 111():110352. PubMed ID: 34015384
[TBL] [Abstract][Full Text] [Related]
17. A Novel Anti-Inflammatory Formulation Comprising Celecoxib and Cannabidiol Exerts Antidepressant and Anxiolytic Effects.
Dinur E; Goldenberg H; Robinson E; Naggan L; Kozela E; Yirmiya R
Cannabis Cannabinoid Res; 2024 Apr; 9(2):561-580. PubMed ID: 36520610
[No Abstract] [Full Text] [Related]
18. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia.
Cortez IL; Silva NR; Rodrigues NS; Pedrazzi JFC; Del Bel EA; Mechoulam R; Gomes FV; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110553. PubMed ID: 35341823
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.
Zanelati TV; Biojone C; Moreira FA; Guimarães FS; Joca SR
Br J Pharmacol; 2010 Jan; 159(1):122-8. PubMed ID: 20002102
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
